| Literature DB >> 36093194 |
Xiaochun Shi1, Bei Gao2, Anvesha Srivastava3, Zahra Izzi4, Yoosif Abdalla3, Weishou Shen1,5, Dominic Raj3.
Abstract
Alterations in gut microbiota might contribute to uremic toxicity and immune dysregulation in patients with end-stage renal disease. Hemodialysis patients are prone to infection and higher mortality following sepsis. The virulence factors in the gut metagenome have not been well studied in hemodialysis patients, which could be employed by microorganisms to successfully thrive and flourish in their hosts. In this study, we performed shotgun metagenomics sequencing on fecal DNA collected from 16 control subjects and 24 hemodialysis patients. Our analysis shows that a number of microbial species, metabolic pathways, antibiotic resistance, and virulence factors were significantly altered in hemodialysis patients compared with controls. In particular, erythromycin resistance methylase, pyridoxamine 5-phosphate oxidase, and streptothricin-acetyl-transferase were significantly increased in hemodialysis patients. The findings in our study laid a valuable foundation to further elucidate the causative role of virulence factors in predisposing HD patients to infection and to develop treatment strategies to reduce the genetic capacities of antibiotic resistance and virulence factors in HD patients.Entities:
Keywords: hemodialysis; metagenome; microbiome; random forest; virulence factor
Mesh:
Substances:
Year: 2022 PMID: 36093194 PMCID: PMC9461950 DOI: 10.3389/fcimb.2022.904284
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Subject characteristics.
| Patient variable | Controls | HD patients |
|
|---|---|---|---|
| Sex female | 10 (67%) | 12 (50%) | 0.491 |
| Age | 64 ± 10 | 57 ± 10 | 0.041 |
| Race | 0.143 | ||
| Asian | 2 (13%) | 0 (0%) | |
| Black | 9 (60%) | 17 (70%) | |
| Caucasian | 4 (27%) | 4 (17%) | |
| Other | 0 (0%) | 3 (13%) | |
| Body mass index (kg/m2) | 30.7 ± 7.6 | 31.8 ± 6.3 | 0.642 |
| Diabetes mellitus | 6 (40%) | 9 (38%) | 0.999 |
| Glucose (mg/dl) | 143.0 ± 88.7 | 123.0 ± 58.6 | 0.455 |
| Blood urea nitrogen (mg/dl) | 12.5 ± 5.4 | 64.5 ± 14.5 | <0.001 |
| Serum creatinine (mg/dl) | 0.9 ± 0.2 | 10.6 ± 1.9 | <0.001 |
| Sodium (mmol/L) | 142.0 ± 2.9 | 139.0 ± 3.0 | 0.005 |
| Potassium (mmol/L) | 4.4 ± 0.4 | 5.7 ± 0.8 | <0.001 |
| Chloride (mmol/L) | 103.0 ± 2.9 | 95.3 ± 3.3 | <0.001 |
| Carbon dioxide (mmol/L) | 24.4 ± 2.7 | 20.2 ± 2.5 | <0.001 |
| Calcium (mg/dl) | 9.5 ± 0.4 | 8.9 ± 0.6 | 0.001 |
| EGFR | 80.9 ± 19.0 | 5.4 ± 1.4 | <0.001 |
Values of the control subjects were within the recommended normal range.
Figure 1Microbial species are altered in HD patients. (A) Alpha-diversity of microbial community assessed by Shannon and Simpson index. (B) Significantly altered microbial species between HD patients and control subjects. (C) Cladogram of significantly altered microbes. (D) Correlations between the gut microbes with clinical data. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001. BUN: blood urea nitrogen.
Figure 2Alterations in microbial pathways. (A) Significantly altered microbial pathways between HD patients and control subjects. (B) Correlation between microbial pathways and clinical parameters. *p-value < 0.05; **p-value < 0.01. BUN, blood urea nitrogen.
Figure 3Alterations in virulence factors. (A) Significantly altered virulence factors between HD patients and control subjects. (B) Distribution of virulence factors in each sample. Data were visualized via Circlize package in R. (C) Correlations between virulence factors and clinical data. *p-value < 0.05; **p-value < 0.01. BUN, blood urea nitrogen.
Figure 4Alterations in antibiotic resistance factors. (A) Significantly altered antibiotic resistance factors between HD patients and control subjects. (B) Distribution of antibiotic resistance factors in each sample. Data were visualized via Circlize package in R. (C) Correlations between antibiotic resistance factors and clinical data. *p-value < 0.05; ***p-value < 0.001. BUN, blood urea nitrogen.
Figure 5Prediction of HD patients with random forest model. (A) Random forest model predicting HD patients from control subjects. (B) Variable importance.